Skip to main content

ALTE1621 Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial

NCT02717507

Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial

Associated Conditions

Companion Study

Principal Investigator

Sponsor

Children's Oncology Group

The main goals of this study are: To compare laboratory tests and other evaluations associated with risk of heart failure between subjects selected by chance (randomization) to take low-dose carvedilol or placebo for 2 years. (Subjects are people who agree to take part in this study). To find out what effects (good and/or bad) carvedilol has on childhood cancer survivors who received high-dose anthracycline chemotherapy by looking at laboratory tests and information on side effects collected from questionnaires. The other goal of this study is: To see if there are factors that may cause you to respond better or worse to carvedilol. These factors include your weight, age at cancer diagnosis, current age, dose of chemotherapy drug, exposure to chest radiation, risk factors for heart disease and genetic features.